Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171011 | 0.85 | PRMT5 (0.35) | MAT2APTGS2PTGS1PRMT5WDR77 | |
| SCHEMBL2215183 | 0.81 | MAT2A (0.34) | MAT2APTGS2PTGS1PRMT5WDR77 | |
| SCHEMBL7945841 | 0.80 | MAT2A (0.34) | MAT2APTGS2PTGS1PRMT5WDR77 | |
| SCHEMBL7948833 | 0.72 | PRMT5 (0.36) | PRMT5WDR77 | |
| SCHEMBL2170670 | 0.69 | PDE4B (0.45) | MAT2APTGS2PTGS1PRMT5WDR77 | |
| SCHEMBL2217605 | 0.68 | LRRK2 (0.34) | PTGS2PTGS1PDE4BPDE3AKCNQ3 | |
| SCHEMBL2172480 | 0.65 | PDE4B (0.51) | PDE4BPDE3A | |
| SCHEMBL2170742 | 0.65 | PRMT5 (0.36) | PTGS2PTGS1PRMT5WDR77PDE4B | |
| SCHEMBL2170274 | 0.65 | PTGS2 (0.35) | MAT2APTGS2PTGS1PDE4BPDE3A | |
| SCHEMBL2217843 | 0.64 | PRMT5 (0.37) | PRMT5WDR77PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | PDE3A, PDE2A, PDE3B | MAT2A 540/4885PTGS2 111/4885PTGS1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.